Health and FitnessHealth and Fitness
Fri, June 15, 2012
Thu, June 14, 2012

Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans


Published on 2012-06-14 15:40:30 - Market Wire
  Print publication without navigation


Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans -- MONTREAL, June 14, 2012 /PRNewswire/ --

Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans

[ ]
[ ]

MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: [ VRX ] and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions.  The incremental term loans will mature in 2019 and have terms that are similar to the Company's existing $600 million Term Loan B facility, with certain modifications. The facility closed on June 14, 2012.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at [ www.valeant.com ].

(Logo: [ http://photos.prnewswire.com/prnh/20101025/LA87217LOGO ])

Contact Information:
Laurie W. Little
949-461-6002
[ laurie.little@valeant.com ]

 

SOURCE Valeant Pharmaceuticals International, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.valeant.com ]